Achieving low-cost sequencing requires high-throughput scale, and most genomics companies cannot reach it alone. In the LSMC fab your samples run in a fully scaled, CLIA-certified lab giving you the cost and consistency of a mature production line at any volume.
When you work with LSMC, our team becomes your expert production line. We help a team decide which genome product to make, what variant classes it needs to support, what quality standard it has to meet, and what deliverable comes back at the end.
From imputed low-pass at population scale to a full short-read and long-read hybrid, LSMC manufactures four genome products against the same quality gate. Choose by the resolution the program needs.
The LSMC team has built and scaled the world’s largest clinical sequencing operations, running millions of samples a year in regulated clinical environments. We know what works at a million samples - and what breaks. It's experience you can rely on from day one.
See how a sample moves through the genome manufacturing workflow and becomes a finished genome data product.
LSMC becomes your production team, giving you a CLIA-certified lab, the flexibility of a contract sequencing provider, and the speed and cost of a scaled facility.
See how LSMC connects program design, genome production, and data delivery in one manufacturing system. A program starts as a specification, and the fab returns it as finished genome data.
Start from the application or from the resolution you already want. The planner translates that choice into product fit, scope gaps, turnaround, and indicative program economics.
The genome products
From low-pass to high-res, our four genome products provide the flexibility you need to meet your requirements and budget.
| Axis | Low-Pass | Cost Opt | Industry Stdselected | High-Res Hybrid |
|---|---|---|---|---|
| 47 | 78 | 85 | 96 | |
| 70 | 92 | 94 | 97 | |
| 45 | 75 | 88 | 96 | |
| – | 18 | 35 | 92 | |
| 20 | 30 | 45 | 92 |
Every run is held to these acceptance criteria at the quality gate. If it does not meet them, it does not ship.
Indicative performance characteristics, projected from validated platform capability. Final figures are firmed up per program against audited production data.
Run at 1–4× depth, the Low-Pass Genome trades per-base certainty for breadth, then imputes common variants from large reference panels. It resolves broad common-variant signal and polygenic scores across populations; common indels are imputed alongside SNVs, while structural variants and anything needing direct full-depth observation are out of scope. It is the lowest-cost path LSMC manufactures.
$A short-read genome tuned for cost. SNVs and small indels are called at clinical grade; copy-number and structural variants come at research grade, not clinical. Full depth, for programs that do not need maximum structural resolution.
$$The LSMC short-read baseline genome, run at full depth on the validated caller stack. It calls SNVs and small indels at clinical grade and resolves most structural variants. The standard genome for programs that need reliable, whole-genome short-read coverage without the long-read arm.
$$$Two sequencing methods in one assay. The short-read arm delivers high base-level accuracy across the whole genome, calling SNVs and small indels, while the long-read arm resolves what short reads cannot: structural variants, repeat expansions, and segmental duplications, and phases the result. The widest-reaching genome LSMC manufactures, clinical-ready across every class.
$$$$Genomics can transform science and medicine, but only if the data that drives innovation can scale. Too much effort today goes into rebuilding the same sequencing operations. LSMC runs that operation once, so its customers do not have to build it again.
The founding team combines genomics product strategy, high-throughput laboratory operations, automation, bioinformatics, and experience scaling clinical sequencing systems.
Eric is known for helping companies make high-conviction bets while avoiding the landmines that derail the move from R&D to commercialization. He has led product, technology, and scientific strategy through growth, scale, and reinvention, aligning scientific rigor with commercial execution.
LinkedInFor over twenty years, John has worked at the forefront of genomics, from contributing to the Human Genome Project to scaling leading genetic-testing companies. He was a leader at Invitae as it grew from a small lab to more than two million samples per year, with deep experience in high-throughput sequencing, bioinformatics, and process automation.
LinkedInJohn has led the design and operation of large-scale clinical genomics laboratories at Labcorp and Invitae. He built hardware, software, and automation systems for one of the world’s largest clinical sequencing operations, where reliability and reproducibility are essential.
LinkedInLSMC reviews each inquiry and responds with a proposed program scope and an indicative price.